Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lyell Reports Dose-dependent Activity from Phase 1 of LYL797, ROR1-targeted CAR-T
Details : LYL797 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) targeted CAR T‑cell product, being developed for ROR1+ triple negative breast cancer or non-small cell lung cancer.
Product Name : LYL797
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 26, 2024
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
Details : LYL845 is an investigational autologous TIL product enhanced with Epi-R manufacturing protocols for patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC and CRC.
Product Name : LYL845
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 11, 2023
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
Details : LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors.
Product Name : LYL797
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 09, 2022
Details : LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. The presentation will highlight the preclinical data characterizing LYL797.
Product Name : LYL797
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 03, 2022
Details : LYL845 is an investigational tumor infiltrating lymphocyte (TIL) therapy enhanced with Lyell’s Epi-R™ technology for patients with relapsed and/or refractory metastatic or locally advanced melanoma and other select solid tumors.
Product Name : LYL845
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 10, 2022
Details : LYL845 is Lyell’s autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced via Epi-R™, a proprietary epigenetic reprogramming technology, designed to create products with higher proportions of stem-like T cells.
Product Name : LYL845
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : LYL132,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GSK4427296 (LYL132) an investigational T-cell receptor, incorporates Epi-R reprogramming technology and is under investigation as a potential next-generation enhancement to letetresgene autoleucel for patients with solid tumors.
Product Name : GSK4427296
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : LYL132,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable